Description

Bonus issue of 1:10 ratio and listing details for Welcure Drugs & Pharmaceuticals Limited (Scrip Code: 524661) with allotment date of October 17, 2025.

Summary

BSE has announced the sub-division and bonus issue details for Welcure Drugs & Pharmaceuticals Limited (Scrip Code: 524661). The company will allot 1,12,35,820 bonus equity shares at a ratio of 1:10 (one bonus share for every ten existing shares). The bonus shares have been allotted on October 17, 2025 (deemed date) and will be effective for listing on October 20, 2025.

Key Points

  • Company: Welcure Drugs & Pharmaceuticals Limited (Scrip Code: 524661, ISIN: INE331C01017)
  • Pre-Allotment Capital: 11,23,58,200 equity shares of Rs. 10/- face value (Rs. 112.36 crore paid-up capital)
  • Bonus Shares Issued: 1,12,35,820 equity shares at Rs. 10/- face value
  • Bonus Ratio: 1:10 (1 bonus share for every 10 existing shares)
  • Post-Allotment Capital: 12,35,94,020 equity shares of Rs. 10/- face value (Rs. 123.59 crore paid-up capital)
  • New Share Distribution Number Range: 11,23,58,201 to 12,35,94,020
  • Board Approval Date: September 27, 2025
  • Shareholder Approval Date: August 22, 2025
  • No reservation or abeyance of bonus shares

Regulatory Changes

No regulatory changes. This is a standard corporate action filing as per SEBI listing regulations for bonus issue disclosure.

Compliance Requirements

  • Shareholders holding shares as on the record date are entitled to bonus shares in 1:10 ratio
  • The company has completed all regulatory approvals (Board and Shareholder approval)
  • Listing formalities to be completed by BSE by the effective listing date

Important Dates

  • August 22, 2025: Shareholder approval for bonus issue
  • September 27, 2025: Board of Directors approval
  • October 17, 2025: Deemed date of allotment of bonus shares
  • October 20, 2025: Effective date of listing for bonus shares

Impact Assessment

Market Impact: Medium. The bonus issue will increase the number of outstanding shares by 10%, improving liquidity and making shares more accessible to retail investors through lower price per share. The 1:10 ratio is moderate and should not significantly dilute per-share metrics since it’s proportional to all shareholders.

Shareholder Impact: Positive for existing shareholders who receive additional shares without any cost. Post-bonus, share price will adjust proportionally, but total holding value remains unchanged.

Trading Impact: Enhanced liquidity expected post-listing on October 20, 2025, as the increased float may attract more market participants.

Contact Information

  • Contact Person: Chintan Didawala Ganpat (Managing Director)
  • Phone: 9662323244
  • Email: welcuredrugs227@gmail.com
  • Registered Office: Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi, 110092

Impact Justification

Bonus issue affects existing shareholders through capital restructuring. Impact limited to single company but significant for its shareholders with 1:10 bonus ratio.